WASHINGTON, April 22,
2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc.
(Vanda) (Nasdaq: VNDA) today announced that the Supreme Court
denied Vanda's petition for a writ of certiorari in its
HETLIOZ® Abbreviated New Drug Application litigation
against Teva Pharmaceuticals USA,
Inc., Apotex Inc. and Apotex Corp.
"We are disappointed that the Supreme Court has decided not to
hear our case and clarify the lower court standard for obviousness
in patent law. However, we are pleased that our case has drawn
attention to an area of law that has broad and significant
implications in life sciences innovation," said Dr. Mihael H. Polymeropoulos, President, CEO and
Chairman of the Board. "We look forward to future cases that may
resolve these issues for the benefit of innovators, patients and
public health."
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on
the development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of patients.
For more on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com and follow us on Twitter @vandapharma.
About HETLIOZ®
For full U.S. Prescribing Information for HETLIOZ®,
including indication and Important Safety Information, visit
www.hetlioz.com.
Corporate Contact:
Kevin
Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan
Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reacts-to-us-supreme-courts-denial-of-its-petition-in-hetlioz-anda-litigation-302123839.html
SOURCE Vanda Pharmaceuticals Inc.
